Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Safety And Efficacy ◽

Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

10.1158/0008-5472.sabcs13-p2-16-10 ◽

2013 ◽

Author(s):

EA Perez ◽

JM López-Vega ◽

L Del Mastro ◽

T Petit ◽

C Zamagni ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet)

Annals of Oncology ◽

10.1016/s0923-7534(20)32976-8 ◽

2012 ◽

Vol 23 ◽

pp. ix142

Author(s):

M. Andersson ◽

J.M. Lopez-Vega ◽

L. Del Mastro ◽

T. Petit ◽

L. Mitchell ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps102 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS102-TPS102 ◽

Cited By ~ 15

Author(s):

P. A. Ellis ◽

C. H. Barrios ◽

Y. Im ◽

M. Patre ◽

F. Branle ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90842-7 ◽

2004 ◽

Vol 2 (3) ◽

pp. 125-126 ◽

Cited By ~ 20

Author(s):

J.M Extra ◽

F Cognetti ◽

D Maranichi ◽

R Snyder ◽

L Mauriac ◽

...

Keyword(s):

Breast Cancer ◽

Multicentre Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Docetaxel and carboplatin followed by sequential capecitabine as first line treatment in patients with locally advanced or metastatic breast cancer.

10.1158/0008-5472.sabcs-2155 ◽

2009 ◽

Author(s):

A Lorenzo ◽

A Modolell ◽

P Valero ◽

L Murillo ◽

JM García-Bueno ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Cited By ~ 6

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

First‐Line Treatment Patterns and Clinical Outcomes in Patients With HER2‐Positive and Hormone Receptor‐Positive Metastatic Breast Cancer From registHER

The Oncologist ◽

10.1634/theoncologist.2012-0414 ◽

2013 ◽

Vol 18 (5) ◽

pp. 501-510 ◽

Cited By ~ 37

Author(s):

Debu Tripathy ◽

Peter A. Kaufman ◽

Adam M. Brufsky ◽

Musa Mayer ◽

Marianne Ulcickas Yood ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Treatment Patterns ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70973-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 285 ◽

Cited By ~ 2

Author(s):

R. Palumbo ◽

A. Bernardo ◽

M.R. Strada ◽

G. Poggi ◽

C. Teragni ◽

...

Keyword(s):

Breast Cancer ◽

Patient Compliance ◽

Metastatic Breast ◽

Line Treatment ◽

Triple Combination ◽

First Line ◽

Her2 Positive ◽

Oral Vinorelbine ◽

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer

Cancer Research and Treatment ◽

10.4143/crt.2021.1103 ◽

2022 ◽

Author(s):

Yong-Pyo Lee ◽

Min-Sang Lee ◽

HongSik Kim ◽

Ji-Yeon Kim ◽

Jin-Seok Ahn ◽

...

Keyword(s):

Breast Cancer ◽

Real World ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Korean Patients ◽

Real World Evidence ◽

Interim Safety and Efficacy of Pertuzumab, Trastuzumab and Vinorelbine for First-Line (1L) Treatment of Patients (Pts) with Her2-Positive Locally Advanced or Metastatic Breast Cancer (Mbc)

Annals of Oncology ◽

10.1093/annonc/mdu329.11 ◽

2014 ◽

Vol 25 ◽

pp. iv120 ◽

Cited By ~ 6

Author(s):

M. Andersson ◽

J.M. Lopez-Vega ◽

T. Petit ◽

C. Zamagni ◽

U. Freudensprung ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Safety And Efficacy